Select Page

US Market Wrap

Wednesday April 24, 2024

S&P +0.0%, Nasdaq +0.1%, Russell -0.3%
10 year note +0.04% at 4.64%

The Top 10 The Super Investor

Articles

Past Results of Australian Funds

Past Results of Australian Funds

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

BHP, Nickel, Iron Ore and China

BHP, Nickel, Iron Ore and China

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

India v China: Value Metrics

India v China: Value Metrics

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Core PCE falls to Fed’s 2% target

Core PCE falls to Fed’s 2% target

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Live to 100, healthy and fit

Live to 100, healthy and fit

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

How To Get Your Dream Job

How To Get Your Dream Job

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Investing Styles That Work

Investing Styles That Work

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Macquarie Bank Hires Teenager

Macquarie Bank Hires Teenager

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Register for our FREE reports here...

You have Successfully Subscribed!

Register for our FREE reports here...

You have Successfully Subscribed!